Field Notes

The work.
Unfiltered.

Real insight on cannabis M&A, commercial acquisitions, and the deals most brokers won't touch. Written from the deal table, not a textbook.

Cannabis M&ACommercial Real EstateBusiness AcquisitionsDue DiligenceLOI & ContractsCDTFA ComplianceDCC LicensingRestricted Markets Cannabis M&ACommercial Real EstateBusiness AcquisitionsDue DiligenceLOI & ContractsCDTFA ComplianceDCC LicensingRestricted Markets
All Posts
The Cannabis Rescheduling Deadline Nobody's Talking About

280E relief is grabbing every headline. Meanwhile, a 60-day federal registration window is closing around June 27 — and missing it puts you on the wrong side of a deal.

The DEA's Rescheduling Announcement Just Made Cannabis Deal Timelines Worse, Not Better

DEA isn't finalizing the May 2024 rule — they're announcing a new hearing. In deal terms, that's not signing the LOI. That's tearing it up and starting over.

280E Is Still Law: Why Cannabis Buyers Pricing Deals on Rescheduling Are Taking on Hidden Risk

The DEA has not published a final rescheduling rule. Buyers pricing acquisitions on post-280E economics are taking on risk they haven't priced.

How to Read California's Cannabis Municipal Calendar as a Deal-Flow Signal

If you're using statewide headlines to time your next acquisition, you're looking at the wrong data. The real leading indicator lives at the city council level.

Coming Soon
Next post in progress
Coming Soon
Next post in progress
Have a deal nobody
else will touch?